ImpediMed Documents
Documents
0
Ticker
IPD.AX
ISIN
AU000000IPD8
ImpediMed SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
ImpediMed Documents 2026
This page contains all official documents and SEC filings for ImpediMed stock (IPD.AX, ISIN: AU000000IPD8). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of ImpediMed's regulatory filings.
ImpediMed Stock analysis
ImpediMed ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion.